ArticleCureus2025
Fatal Case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Induced by Doxycycline or Flucloxacillin in a 77-Year-Old Woman: A Rare but Serious Adverse Drug Reaction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Effects of Nursing Care Applied in the Intensive Care Unit on a Case of Toxic Epidermal Necrolysis: A Case Report.Nursing in critical care · 2026Article
- Research progress on potential high-risk drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis with insights from adverse drug reaction database mining.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome (SJS) is a serious, potentially life-threatening condition affecting the skin and mucous membranes. This syndrome occurs twice as frequently in females compared to males and affects individuals across all age groups. The most common triggers are drugs. Here, we present a case of SJS linked to doxycycline/flucloxacillin-induced SJS. A 76-year-old woman with Sjögren's syndrome, rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD), and osteoarthritis (OA) was referred by her General Practitioner (GP) with a rapidly spreading, itchy, hyperkeratotic rash involving >80% body surface area (BSA), which began on the lower abdomen two days prior. She had received flucloxacillin, doxycycline, and topical steroids, after which the rash worsened. With no known drug allergies, the medications were discontinued, and she was referred for further care. On examination, she had extensive flaky, eruptive lesions with a positive Nikolsky sign. Skin biopsy and immunohistochemistry confirmed widespread epidermal necrosis. A provisional diagnosis of drug-induced toxic epidermal necrolysis (TEN) was made, with flucloxacillin or doxycycline suspected as causative agents. She was started on IV teicoplanin and clindamycin, and received methylprednisolone for three days, followed by intravenous immunoglobulin (IVIG). Dermatology was consulted, and daily swabs and labs were conducted to monitor for infection. Despite intensive care and an initial improvement in Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN), her condition deteriorated, and she ultimately succumbed to progressive TEN. This case aims to comprehensively document the clinical progression and therapeutic interventions in a fatal presentation of suspected drug-induced TEN. Management of SJS typically involves discontinuation of the likely drug, hospitalization, and supportive care. Though prompt drug withdrawal was implemented, the patient's condition continued to deteriorate, underscoring the severity of the syndrome. This case highlights a rare instance of doxycycline and flucloxacillin-induced SJS in the elderly. It is crucial to identify and recognize this uncommon but potentially life-threatening adverse reaction to doxycycline and flucloxacillin in general practice when prescribed to elderly individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.